Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label fremanezumab study in pediatric migraine
NL-OMON56148Phase 3Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fremanezumab in migraine and chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Occurrence of adverse events, Clinical laboratory changes and 4 more. Started Aug 2022; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on NL-OMON56148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56148.